Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.
The Diagnostic Validity and Clinical Impact of Blood-based Biomarkers for the Diagnosis of Alzheimer's Disease at the Primary Care Level.
Universitaire Ziekenhuizen KU Leuven
240 participants
May 26, 2026
INTERVENTIONAL
Conditions
Summary
The goal of this study is to determine how blood biomarker tests (ptau217 and ptau217/Aβ42) performed in primary care influence the patient trajectory in individuals with cognitive concerns. Participants will provide a blood sample for biomarker testing and undergo clinical assessments as part of diagnostic evaluation.
Eligibility
Inclusion Criteria1
- Patients between 55 and 85 years old who consult their PCP due to concerns about their cognitive status.
Exclusion Criteria3
- Comorbidities that would interfere with study cooperation or interpretability of study results (for instance substance abuse or cardiac, renal or hepatic failure).
- Concomitant medications that would interfere with cognitive assessments.
- A prior diagnosis of AD and related disorders or other neurodegenerative disease.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human K2EDTA plasma.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07666113